If you or a loved one developed uncontrollable facial or body movements after taking Reglan, you may be wondering whether stopping the drug will make them go away. Research shows that for many, tardive dyskinesia can persist or even appear after discontinuation. Building on decades of patient safety research, this page summarizes key studies on outcomes after stopping Reglan and what the evidence means for your health.
Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux that has not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information instructs clinicians to use Reglan for the shortest duration of treatment and to periodically reassess the need for continued therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the label advises avoiding a total duration of treatment with metoclopramide products, including Reglan tablets, for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label further warns that Reglan is not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central concern. The boxed warning clearly states the risk, but the label also notes that metoclopramide may suppress signs of TD, which could lead to delayed diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients who developed TD after using Reglan, settlement-related considerations often involve the timeline between exposure and documented harm. The label indicates that risk increases with longer treatment duration and higher cumulative doses, but TD can occur even with short-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
In Ohio, the statute of limitations for personal injury claims, including those related to prescription drug injuries like TD, generally requires filing within two years from the date the injury was discovered or reasonably should have been discovered. For TD, this discovery date may be when a patient first notices involuntary movements or when a physician diagnoses the condition. Given that TD can be irreversible and may develop months or years after starting Reglan, patients should be aware that the clock for legal action may start ticking upon diagnosis or when symptoms become apparent. For affected patients in Ohio, settlement considerations include documenting the duration of Reglan use, the cumulative dosage, and the timing of TD symptom onset relative to treatment. The label's warning that Reglan is contraindicated in patients with a history of TD underscores the importance of medical history review before prescribing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who developed TD after using Reglan for longer than the recommended 12-week period may have stronger claims, as the label explicitly advises against extended use. However, even patients who used Reglan within the approved duration may still develop TD, and the label acknowledges that risk exists regardless of treatment length. In summary, the evidence from the Reglan label establishes a clear link between metoclopramide and TD, with specific warnings about duration, dosage, and monitoring. For Ohio patients considering legal action, the statute of limitations requires prompt action after discovery of harm. Settlement-related factors include the adequacy of warnings provided by prescribers and manufacturers, the timeline of exposure and symptom onset, and the documented harm from TD. Patients should consult with a qualified attorney to evaluate their individual circumstances and ensure compliance with Ohio's filing deadlines.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
In Ohio, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or reasonably should have been discovered. This discovery date may be when a patient first notices involuntary movements or when a physician diagnoses the condition. It is crucial to act promptly after discovery to preserve legal rights.
Tardive dyskinesia is characterized by potentially irreversible involuntary movements, as stated in the Reglan prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). While some cases may improve after discontinuation of the drug, the condition can be permanent. Early detection and cessation of Reglan may reduce the risk of progression, but reversal is not guaranteed.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.